The Polymorphism and Transformation of (3aRS, 4RS, 7RS, 7aSR)-2-(Tricyclo(3.3.1.13,7)decan-1-yl)-4,5,6,7- tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162)—A Novel Anticancer Compound

@article{Huang2014ThePA,
  title={The Polymorphism and Transformation of (3aRS, 4RS, 7RS, 7aSR)-2-(Tricyclo(3.3.1.13,7)decan-1-yl)-4,5,6,7- tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162)—A Novel Anticancer Compound},
  author={Yuqing Huang and Zaiyou Tan and Lin Luo and Hui Yang and Chunmei Tong and Wenfei Chen and Tingyu Huang and Ruiling Liu},
  journal={Journal of Crystallization Process and Technology},
  year={2014},
  volume={04},
  pages={27-30}
}
Objective: To determine the transformation between two known crystal forms of the title compound (C18H23NO3, Mr = 301.37). Methods: To recrystallize or heat the crystals and determine the crystal form by testing the melting points. Results: Both the two known crystal forms of the title compound can be changed by dissolving into different organic solvents such as acetone and ethyl acetate. Crystal form I was not influenced by heating while crystal form II can be transformed to crystal form I… 

Figures and Tables from this paper

Preparation and Characterization of Two Polymorphs of (3aRS,4RS,7RS,7aSR)-2- (Tricyclo(3.3.1.1 3,7 )decan-1-yl)-4,5,6,7- tetrahydro-4,7-eposyisoindoline-1,3- dione (SU2162) with PXRD and DSC

Objective: To develop the characterization of the polymorphs and the best preparation method of two forms of the title compound (SU2162). After SU2162 was prepared in accordance with the patent

References

SHOWING 1-7 OF 7 REFERENCES

Preparation and X-ray diffraction analysis of a new crystal form of(3aRS,4RS,7RS,7aSR)-2-(tricyclo[3.3.1.1~(3,7)]decan-1-yl)-4,5,6,7-tetrahydro-4,7-epoxyisoindoline-1,3-dione-a novel anticancer compound

Objective To determine a new crystal form of the title compound(C18H23NO3,Mr=301.37).Methods To prepare the crystals and determine the crystal structure by single-crystal X-ray diffraction.Results

Applications of process analytical technology to crystallization processes.

An overview of pharmaceutical cocrystals as intellectual property.

  • A. V. Trask
  • Materials Science
    Molecular pharmaceutics
  • 2007
An outlook is provided on how the developing field of cocrystallization may impact the pharmaceutical intellectual property landscape and several potential commercial advantages of pharmaceutical cocrystals are highlighted.

Cancer statistics, 2013

Overall cancer death rates have declined 20% from their peak in 1991 to 2009 and can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket and other underserved populations.

3aRS, 4RS, 7RS, 7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahy dro-4,7-eposyisoindoline-1,3-dione

  • Acta Crystallographica, Vol. E66, 2010, Article ID: o1374.
  • 2010

A Method of Inhibiting Platelet Aggregation, Anti-Thrombosis Ferulic Acid Crystal and Preparation Method

  • TMP: China Patent No. ZL201010562477.0, 2013.
  • 2010

Preparation of a Derivative of Cantharidin with Anticancer Activity

  • China Patent No. 200710029736, 2008/
  • 2007